Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis
characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against …
characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against …
Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis associated
with significant morbidity and mortality that has historically been treated with systemic …
with significant morbidity and mortality that has historically been treated with systemic …
Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
ME Wechsler, P Akuthota, D Jayne… - … England Journal of …, 2017 - Mass Medical Soc
Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …
Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis
Background Eosinophilic granulomatosis with polyangiitis (EGPA), a rare vasculitis with
substantial morbidity, is characterized by asthma, eosinophilia, sinusitis, pulmonary …
substantial morbidity, is characterized by asthma, eosinophilia, sinusitis, pulmonary …
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
S Nolasco, A Portacci, R Campisi… - Frontiers in …, 2023 - frontiersin.org
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis
characterized by asthma, systemic manifestations, and blood and tissue eosinophilia …
characterized by asthma, systemic manifestations, and blood and tissue eosinophilia …
[HTML][HTML] Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis
J Steinfeld, ES Bradford, J Brown, S Mallett… - Journal of Allergy and …, 2019 - Elsevier
Background In a recent phase III trial (NCT02020889) 53% of mepolizumab-treated versus
19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) …
19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) …
Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study
A Canzian, N Venhoff, ML Urban… - Arthritis & …, 2021 - Wiley Online Library
Objective To describe the efficacy and safety of biologics for the treatment of eosinophilic
granulomatosis with polyangiitis (EGPA). Methods A retrospective European collaborative …
granulomatosis with polyangiitis (EGPA). Methods A retrospective European collaborative …
Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study
Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …
Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases
Z Celebi Sozener, B Gorgulu, D Mungan… - World Allergy …, 2018 - Springer
Background Data are limited regarding the effectiveness of omalizumab in patients with
eosinophilic granulomatosis with polyangiitis (EGPA). Our aim was to evaluate the clinical …
eosinophilic granulomatosis with polyangiitis (EGPA). Our aim was to evaluate the clinical …
Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
V Teixeira, AJ Mohammad, RB Jones, R Smith… - RMD open, 2019 - rmdopen.bmj.com
Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of
antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct …
antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct …